Friday, 22 Jun 2018

You are here

One-Third of FDA Approvals Need Post-Marketing Safety Changes

One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)

An analysis by the Food and Drug Administration (FDA), looked at all 222 prescription drugs (183 pharmaceuticals and 39 biologics) approved between 2001 through 2010.

They identified 71 new drugs with 123 new postmarket safety events (3 withdrawals, 61 boxed warnings, and 59 safety communications) during a follow-up period of 11.7 years. The overall proportion drugs affected by a postmarket safety event at 10 years was 32%.  The median time from approval to first postmarket safety event was 4.2 years.

These events resulted in either black-box warnings and lesser alerts (warnings, cautions) for many of these drugs, with only 3 being withdrawn from th market (Bextra, Raptiva, Zelnorm).

These findings were significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93), psychiatric agents, those drugs receiving accelerated approval and those with near–regulatory deadline approval. 

Post-marketing safety events were found in 32% of new drugs approved by the FDA from 2001 through 2010. Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval agents were at greater risk for new, evolvig safety events, suggesting an ongoing need for pharmacovigilance with new agents.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.